RESEARCH TRIANGLE PARK, N.C. – April 9, 2015 – For the third time in the last four years, Quintiles has been named Best Clinical Research Organization (CRO) at the Vaccine Industry Excellence (ViE) Awards. Presented at the World Vaccine Congress in Washington, D.C., the awards recognize the efforts and achievements of companies and individuals in the vaccine industry during the previous year.

“We are honored to once again receive this prestigious award reflecting the insight of many from across the biopharmaceutical industry,” said Phil Breitfeld, vice president and head of the Therapeutic Centers of Excellence at Quintiles. “It is clear to us all that the healthcare industry has a tremendous opportunity to conquer the global burden of disease. We’re proud to be working alongside our customers to develop and commercialize vaccines and anti-infective products that contribute to those efforts and can help create a healthier world.”

The Best CRO award winner is selected by leaders from biopharmaceutical companies and other industry experts who vote online for their preferred provider prior to the World Vaccine Congress. Each nominated company also is scored by a judging panel based on the following criteria:

  • Range of services provided in niche and core therapeutic areas
  • Methods of performance improvement or introduction of new services
  • Attention to and quality of relationships with clients
  • Reaching of milestones and final/ongoing outcomes
  • Building and maintaining existing and long-term partnerships

“We believe our extensive expertise in all phases of vaccine clinical trials, from early clinical development to real-world and late phase capabilities as well as commercial, advisory services and laboratory support helped garner this award,” said Breitfeld.

For more information on Quintiles’ vaccine expertise, go to

About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit

Contact: Mari Mansfield, Media Relations (
+1.919.998.2639 (office) +1.919.259.3298 (mobile)

Karl Deonanan, Investor Relations (